Literature DB >> 27473101

Two-miRNA classifiers differentiate mutation-negative follicular thyroid carcinomas and follicular thyroid adenomas in fine needle aspirations with high specificity.

Tomasz Stokowy1,2, Bartosz Wojtas2,3, Barbara Jarzab2, Knut Krohn4, David Fredman5, Henning Dralle6, Thomas Musholt7, Steffen Hauptmann8, Dariusz Lange9, László Hegedüs10, Ralf Paschke11, Markus Eszlinger12,13.   

Abstract

Diagnosis of thyroid by fine needle aspiration is challenging for the "indeterminate" category and can be supported by molecular testing. We set out to identify miRNA markers that could be used in a diagnostic setting to improve the discrimination of mutation-negative indeterminate fine needle aspirations. miRNA high-throughput sequencing was performed for freshly frozen tissue samples of 19 RAS and PAX8/PPARG mutation-negative follicular thyroid carcinomas, and 23 RAS and PAX8/PPARG mutation-negative follicular adenomas. Differentially expressed miRNAs were validated by quantitative polymerase chain reaction in a set of 44 fine needle aspiration samples representing 24 follicular thyroid carcinomas and 20 follicular adenomas. Twenty-six miRNAs characterized by a significant differential expression between follicular thyroid carcinomas and follicular adenomas were identified. Nevertheless, since no single miRNA had satisfactory predictive power, classifiers comprising two differentially expressed miRNAs were designed with the aim to improve the classification. Six two-miRNA classifiers were established and quantitative polymerase chain reaction validated in fine needle aspiration samples. Four out of six classifiers were characterized by a high specificity (≥94 %). The best two-miRNA classifier (miR-484/miR-148b-3p) identified thyroid malignancy with a sensitivity of 89 % and a specificity of 87 %. The high-throughput sequencing allowed the identification of subtle differences in the miRNA expression profiles of follicular thyroid carcinomas and follicular adenomas. While none of the differentially expressed miRNAs could be used as a stand-alone malignancy marker, the validation results for two-miRNA classifiers in an independent set of fine needle aspirations are very promising. The ultimate evaluation of these classifiers for their capability of discriminating mutation-negative indeterminate fine needle aspirations will require the evaluation of a sufficiently large number of fine needle aspirations with histological confirmation.

Entities:  

Keywords:  Classifier; Fine needle aspiration cytology; Follicular thyroid adenoma; Follicular thyroid cancer; High-throughput sequencing; miRNA

Mesh:

Substances:

Year:  2016        PMID: 27473101     DOI: 10.1007/s12020-016-1021-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  27 in total

Review 1.  CLINICAL PRACTICE. Thyroid Nodules.

Authors:  Kenneth D Burman; Leonard Wartofsky
Journal:  N Engl J Med       Date:  2015-12-10       Impact factor: 91.245

2.  A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas.

Authors:  Tomasz Stokowy; Bartosz Wojtaś; Jolanta Krajewska; Ewa Stobiecka; Henning Dralle; Thomas Musholt; Steffen Hauptmann; Dariusz Lange; László Hegedüs; Barbara Jarząb; Knut Krohn; Ralf Paschke; Markus Eszlinger
Journal:  Mol Cell Endocrinol       Date:  2014-09-26       Impact factor: 4.102

3.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

4.  Molecular testing of thyroid fine-needle aspirations improves presurgical diagnosis and supports the histologic identification of minimally invasive follicular thyroid carcinomas.

Authors:  Markus Eszlinger; Simonetta Piana; Anja Moll; Eileen Bösenberg; Alessandra Bisagni; Alessia Ciarrocchi; Moira Ragazzi; Ralf Paschke
Journal:  Thyroid       Date:  2015-02-26       Impact factor: 6.568

5.  miRNAs with the potential to distinguish follicular thyroid carcinomas from benign follicular thyroid tumors: results of a meta-analysis.

Authors:  T Stokowy; B Wojtaś; K Fujarewicz; B Jarząb; M Eszlinger; R Paschke
Journal:  Horm Metab Res       Date:  2014-01-20       Impact factor: 2.936

6.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

Review 7.  Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.

Authors:  Markus Eszlinger; Ralf Paschke
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

Review 8.  Classification of follicular cell-derived thyroid cancer by global RNA profiling.

Authors:  Maria Rossing
Journal:  J Mol Endocrinol       Date:  2013-03-18       Impact factor: 5.098

9.  In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma.

Authors:  Michal Swierniak; Anna Wojcicka; Malgorzata Czetwertynska; Elzbieta Stachlewska; Monika Maciag; Wieslaw Wiechno; Barbara Gornicka; Magdalena Bogdanska; Lukasz Koperski; Albert de la Chapelle; Krystian Jazdzewski
Journal:  J Clin Endocrinol Metab       Date:  2013-06-19       Impact factor: 5.958

10.  Analysis options for high-throughput sequencing in miRNA expression profiling.

Authors:  Tomasz Stokowy; Markus Eszlinger; Michał Świerniak; Krzysztof Fujarewicz; Barbara Jarząb; Ralf Paschke; Knut Krohn
Journal:  BMC Res Notes       Date:  2014-03-13
View more
  9 in total

Review 1.  Molecular profiling of thyroid nodule fine-needle aspiration cytology.

Authors:  Markus Eszlinger; Lorraine Lau; Sana Ghaznavi; Christopher Symonds; Shamir P Chandarana; Moosa Khalil; Ralf Paschke
Journal:  Nat Rev Endocrinol       Date:  2017-03-31       Impact factor: 43.330

Review 2.  Thyroid nodules and cancer management guidelines: comparisons and controversies.

Authors:  Fadi Nabhan; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2016-12-13       Impact factor: 5.678

3.  miR-484/MAP2/c-Myc-positive regulatory loop in glioma promotes tumor-initiating properties through ERK1/2 signaling.

Authors:  Renhui Yi; Jiugeng Feng; Shaochun Yang; Xiaoyu Huang; Yuanyuan Liao; Zheng Hu; Muyun Luo
Journal:  J Mol Histol       Date:  2018-02-26       Impact factor: 2.611

Review 4.  MicroRNAs as Biomarkers in Thyroid Carcinoma.

Authors:  Marilena Celano; Francesca Rosignolo; Valentina Maggisano; Valeria Pecce; Michelangelo Iannone; Diego Russo; Stefania Bulotta
Journal:  Int J Genomics       Date:  2017-09-06       Impact factor: 2.326

5.  Reciprocal Dysregulation of MiR-146b and MiR-451 Contributes in Malignant Phenotype of Follicular Thyroid Tumor.

Authors:  Margarita Knyazeva; Ekaterina Korobkina; Alexey Karizky; Maxim Sorokin; Anton Buzdin; Sergey Vorobyev; Anastasia Malek
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

Review 6.  miR-484: A Potential Biomarker in Health and Disease.

Authors:  Yin-Zhao Jia; Jing Liu; Geng-Qiao Wang; Zi-Fang Song
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

7.  Integrated microRNA-mRNA analyses of distinct expression profiles in follicular thyroid tumors.

Authors:  Jiadong Chi; Xiangqian Zheng; Ming Gao; Jingzhu Zhao; Dapeng Li; Jiansen Li; Li Dong; Xianhui Ruan
Journal:  Oncol Lett       Date:  2017-10-06       Impact factor: 2.967

Review 8.  Update on Fundamental Mechanisms of Thyroid Cancer.

Authors:  Alessandro Prete; Patricia Borges de Souza; Simona Censi; Marina Muzza; Nicole Nucci; Marialuisa Sponziello
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-13       Impact factor: 5.555

Review 9.  Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.

Authors:  Myriem Boufraqech; Naris Nilubol
Journal:  Cancers (Basel)       Date:  2019-12-10       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.